AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- RV01, a Lu177-labelled B7-H3-targeted monoclonal antibody, showed favourable biodistribution and sustained high tumour uptake in preclinical studies.
- RV01 incorporates Fc region modifications to shorten its half-life, potentially reducing off-target radiation exposure and associated toxicities.
- Radiopharm plans to submit an Investigational New Drug (IND) application by mid-2025, with a first-in-human basket study expected to begin by year-end.
Radiopharm Theranostics’ (ASX:RAD, Nasdaq:RADX) share price jumped over 16% to AUD 0.028 on 2 June 2025, following the release of latest preclinical data for its B7-H3-targeted radiopharmaceutical therapy, RV01.
Preclinical studies using the Lu177-B7H3-monoclonal antibody (RV01) showed favourable biodistribution and sustained high tumour uptake. The engineered modifications to the monoclonal antibody (mAb) resulted in a shorter lifespan compared to traditional mAbs. These changes, along with other Fc modifications, helps minimise off-target exposure to the isotope and reduce toxicities commonly associated with conventional mAb therapies.
